376 related articles for article (PubMed ID: 25029236)
41. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.
Kordes S; Richel DJ; Klümpen HJ; Weterman MJ; Stevens AJ; Wilmink JW
Invest New Drugs; 2013 Feb; 31(1):85-91. PubMed ID: 22367239
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
[TBL] [Abstract][Full Text] [Related]
43. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
Fury MG; Sherman E; Ho AL; Xiao H; Tsai F; Nwankwo O; Sima C; Heguy A; Katabi N; Haque S; Pfister DG
Cancer; 2013 May; 119(10):1823-31. PubMed ID: 23408298
[TBL] [Abstract][Full Text] [Related]
44. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Hill ME; Li X; Kim S; Campbell A; Culler K; Bloomston M; Zalupski M; Hejna G; Bekaii-Saab T
Cancer Chemother Pharmacol; 2011 Mar; 67(3):511-7. PubMed ID: 20461379
[TBL] [Abstract][Full Text] [Related]
45. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
Crane CH; Antolak JA; Rosen II; Forster KM; Evans DB; Janjan NA; Charnsangavej C; Pisters PW; Lenzi R; Papagikos MA; Wolff RA
Int J Gastrointest Cancer; 2001; 30(3):123-32. PubMed ID: 12540024
[TBL] [Abstract][Full Text] [Related]
46. A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer.
Löhr JM; Karimi M; Omazic B; Kartalis N; Verbeke CS; Berkenstam A; Frödin JE
Pancreatology; 2016; 16(4):640-5. PubMed ID: 27234064
[TBL] [Abstract][Full Text] [Related]
47. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Rangwala F; Bendell JC; Kozloff MF; Arrowood CC; Dellinger A; Meadows J; Tourt-Uhlig S; Murphy J; Meadows KL; Starr A; Broderick S; Brady JC; Cushman SM; Morse MA; Uronis HE; Hsu SD; Zafar SY; Wallace J; Starodub AN; Strickler JH; Pang H; Nixon AB; Hurwitz HI
Invest New Drugs; 2014 Aug; 32(4):700-9. PubMed ID: 24711126
[TBL] [Abstract][Full Text] [Related]
48. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
McRee AJ; Davies JM; Sanoff HG; Goldberg RM; Bernard S; Dees EC; Keller K; Ivanova A; O'Neil BH
Cancer Chemother Pharmacol; 2014 Jul; 74(1):117-23. PubMed ID: 24819684
[TBL] [Abstract][Full Text] [Related]
49. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
[TBL] [Abstract][Full Text] [Related]
50. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
[TBL] [Abstract][Full Text] [Related]
51. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Davis SL; Cardin DB; Shahda S; Lenz HJ; Dotan E; O'Neil BH; Kapoun AM; Stagg RJ; Berlin J; Messersmith WA; Cohen SJ
Invest New Drugs; 2020 Jun; 38(3):821-830. PubMed ID: 31338636
[TBL] [Abstract][Full Text] [Related]
52. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
[TBL] [Abstract][Full Text] [Related]
53. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
Shan YS; Lin PW
Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
[TBL] [Abstract][Full Text] [Related]
54. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
Mahipal A; Tella SH; Kommalapati A; Goyal G; Soares H; Neuger A; Copolla D; Kim J; Kim R
Invest New Drugs; 2019 Jun; 37(3):473-481. PubMed ID: 30298303
[TBL] [Abstract][Full Text] [Related]
55. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
56. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Ma WW; Xie H; Fetterly G; Pitzonka L; Whitworth A; LeVea C; Wilton J; Mantione K; Schihl S; Dy GK; Boland P; Iyer R; Tan W; Brady W; Straubinger RM; Adjei AA
Am J Clin Oncol; 2019 Feb; 42(2):184-189. PubMed ID: 30418178
[TBL] [Abstract][Full Text] [Related]
57. Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
Fuxius S; Mross K; Mansouri K; Unger C
Anticancer Drugs; 2002 Oct; 13(9):899-905. PubMed ID: 12394252
[TBL] [Abstract][Full Text] [Related]
58. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
[TBL] [Abstract][Full Text] [Related]
59. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
O'Reilly EM; Roach J; Miller P; Yu KH; Tjan C; Rosano M; Krause S; Avery W; Wolf J; Flaherty K; Nix D; Ryan DP
Oncologist; 2017 Dec; 22(12):1429-e139. PubMed ID: 29158367
[TBL] [Abstract][Full Text] [Related]
60. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
